Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

Key Inclusion Criteria:

1. Patients must be ≥ 18 years of age at the time of signing the informed consent form (ICF)

2. The Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2

3. Patient must be a candidate for serial bone marrow aspirate and/or biopsy accordingto the institutions guidelines and must be willing to undergo a bone marrowaspirate.

4. Patients must have one of the following for eligibility into the study:

5. In dose optimization and expansion: IPSS-R defined very low, low orintermediate risk Myelodysplastic Syndrome (LR MDS) who failed to respond to ordid not tolerate ESAs or luspatercept or HMAs and patients with del 5q whofailed to respond to or did not tolerate lenalidomide; or

6. In dose optimization and expansion: IPSS-R defined very low, low orintermediate risk Chronic Myelomonocytic Leukemia (LR CMML) who failed torespond to or did not tolerate hydroxyurea or HMAs.

Key Exclusion Criteria:

1. Systemic antineoplastic therapy (including cytotoxic chemotherapy, alpha-interferon,kinase inhibitors or other targeted small molecules, and toxin-immunoconjugates) orany experimental therapy within 28 days or 5 half-lives, whichever is longer, andrecovered from the toxicities before the first dose of study treatment. For patientsthat received antibodies the washout period is 4 weeks prior to study treatment.

2. History of hypersensitivity to the study treatment or its excipients or to drugs ofsimilar chemical classes.

3. Patients who have previously been treated with agents that have the same mechanismof action as DFV890 as defined in Table 6-8, list of prohibited medications (e.g.,drugs targeting the NLRP3 inflammasome pathway and the IL-1 pathway (canakinumab andanakinra)).

4. Use of hematopoietic colony-stimulating growth factors (e.g., G-CSF, GM-CSF, M-CSF),thrombopoietin mimetics or erythroid stimulating agents anytime ≤ 1 week (or 5 halflives, whichever is longer) prior to start of study treatment.

5. Patients receiving:

6. concomitant medications that are known to be modulators of cytochrome P450enzymes CYP2C9 and/or CYP3A (specifically strong or moderate inducers ofCYP2C9, strong inducers of CYP3A enzymes, strong inhibitors of CYP2C9 and/orstrong or moderate dual inhibitors of CYP2C9/CYP3A); and

7. patients, who are poor CYP2C9 metabolizers receiving concomitant medicationsknown to be strong or moderate inhibitors of CYP3A, whose concomitantmedications cannot be discontinued or switched to a different medication within 5 half-lives or 1 week (whichever is longer) prior to start of study treatmentand for duration of the study. See Section 6.8 and list of prohibited drugs inAppendix 8 for more details.

Other protocol-defined inclusion/exclusion criteria may apply.